G-CSF-primed peripheral blood progenitor cells (PBPC) support in high-riskEwing sarcoma of childhood

Since 1993 pediatric patients affected by high-risk Ewing sarcoma for the p resence at onset of a large pelvic mass and/or metastatic disease, were enr olled in a national pilot study comprehensive, finally, of a high-dose chem otherapy (HDCT) procedure with hemopoietic stem cell support. The HDCT proc edure considered as consolidation of the disease status obtained after the first-line therapy was followed by the reinfusion of granulokine colony-sti mulating factor-primed (G-CSF) peripheral blood progenitor cell (PBPCT), He re we present the results in terms of treatment-related toxicity, hospitali zation and rescue of the bone marrow function, in 17 pediatric patients enr olled in such a pilot protocol and submitted to HDCT and PBPCT at the end o f first-line therapy.